92 related articles for article (PubMed ID: 28852849)
1. The serine protease inhibitor of Kazal-type 7 (SPINK7) is expressed in human skin.
Weber C; Fischer J; Redelfs L; Rademacher F; Harder J; Weidinger S; Wu Z; Meyer-Hoffert U
Arch Dermatol Res; 2017 Nov; 309(9):767-771. PubMed ID: 28852849
[TBL] [Abstract][Full Text] [Related]
2. TNF-α and IL-17A induce the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugihara S; Sugimoto S; Tachibana K; Kobashi M; Nomura H; Miyake T; Hirai Y; Yamasaki O; Morizane S
J Dermatol Sci; 2019 Oct; 96(1):26-32. PubMed ID: 31501002
[TBL] [Abstract][Full Text] [Related]
3. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
5. The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses.
Azouz NP; Ynga-Durand MA; Caldwell JM; Jain A; Rochman M; Fischesser DM; Ray LM; Bedard MC; Mingler MK; Forney C; Eilerman M; Kuhl JT; He H; Biagini Myers JM; Mukkada VA; Putnam PE; Khurana Hershey GK; Kottyan LC; Wen T; Martin LJ; Rothenberg ME
Sci Transl Med; 2018 Jun; 10(444):. PubMed ID: 29875205
[TBL] [Abstract][Full Text] [Related]
6. Expression of serine protease inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D
Kobashi M; Morizane S; Sugimoto S; Sugihara S; Iwatsuki K
Br J Dermatol; 2017 Jun; 176(6):1525-1532. PubMed ID: 27797397
[TBL] [Abstract][Full Text] [Related]
7. Attenuated kallikrein-related peptidase activity disrupts desquamation and leads to stratum corneum thickening in human skin equivalent models.
McGovern JA; Meinert C; de Veer SJ; Hollier BG; Parker TJ; Upton Z
Br J Dermatol; 2017 Jan; 176(1):145-158. PubMed ID: 27442805
[TBL] [Abstract][Full Text] [Related]
8. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.
Komatsu N; Saijoh K; Toyama T; Ohka R; Otsuki N; Hussack G; Takehara K; Diamandis EP
Br J Dermatol; 2005 Aug; 153(2):274-81. PubMed ID: 16086736
[TBL] [Abstract][Full Text] [Related]
9. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
Komatsu N; Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
J Invest Dermatol; 2003 Sep; 121(3):542-9. PubMed ID: 12925213
[TBL] [Abstract][Full Text] [Related]
10. Expression of IL-33 in the epidermis: The mechanism of induction by IL-17.
Meephansan J; Komine M; Tsuda H; Karakawa M; Tominaga S; Ohtsuki M
J Dermatol Sci; 2013 Aug; 71(2):107-14. PubMed ID: 23764374
[TBL] [Abstract][Full Text] [Related]
11. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides.
Komatsu N; Takata M; Otsuki N; Ohka R; Amano O; Takehara K; Saijoh K
J Invest Dermatol; 2002 Mar; 118(3):436-43. PubMed ID: 11874482
[TBL] [Abstract][Full Text] [Related]
12. The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.
Redelfs L; Fischer J; Weber C; Wu Z; Meyer-Hoffert U
Arch Dermatol Res; 2016 Mar; 308(2):133-7. PubMed ID: 26746658
[TBL] [Abstract][Full Text] [Related]
13. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
14. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI.
Bennett K; Callard R; Heywood W; Harper J; Jayakumar A; Clayman GL; Di WL; Mills K
J Proteome Res; 2010 Aug; 9(8):4289-94. PubMed ID: 20533828
[TBL] [Abstract][Full Text] [Related]
15. ECRG2/SPINK7 Tumor Suppressor as Modulator of DNA Damage Response.
Patel H; Sheikh MS; Huang Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892042
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of murine SPINK12, a potential orthologue of human LEKTI2.
Reiss K; Meyer-Hoffert U; Fischer J; Sperrhacke M; Wu Z; Dimitrieva O; Krenek P; Suchanova S; Buryova H; Brauer R; Sedlacek R
Exp Dermatol; 2011 Nov; 20(11):905-10. PubMed ID: 21899598
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
18. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha.
Yoshida A; Kanno H; Watabe D; Akasaka T; Sawai T
Arch Dermatol Res; 2008 Jan; 300(1):37-45. PubMed ID: 17960400
[TBL] [Abstract][Full Text] [Related]
19. The solution structure of the kallikrein-related peptidases inhibitor SPINK6.
Jung S; Fischer J; Spudy B; Kerkow T; Sönnichsen FD; Xue L; Bonvin AM; Goettig P; Magdolen V; Meyer-Hoffert U; Grötzinger J
Biochem Biophys Res Commun; 2016 Feb; 471(1):103-8. PubMed ID: 26828269
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
